Patents Issued in July 30, 2024
-
Patent number: 12048733Abstract: The present invention relates to methods of treating an auditory disorder. In particular, the present invention relates to treating an auditory disorder using supraparticles comprising a therapeutic payload.Type: GrantFiled: May 25, 2022Date of Patent: July 30, 2024Assignees: THE BIONICS INSTITUTE OF AUSTRALIA, THE UNIVERSITY OF MELBOURNEInventors: Andrew Wise, Robert K. Shepherd, Frank Caruso
-
Patent number: 12048734Abstract: Methods and compositions are disclosed for treating and preventing cytokine release syndrome (CRS), acute respiratory distress syndrome (CRS), and alveolar capillary injury (ACI) in a subject.Type: GrantFiled: April 16, 2021Date of Patent: July 30, 2024Assignee: OP-T LLCInventors: David H. Wagner, Jr., Gisela M. Vaitaitis, Charles W. Henry, Martin G. Yussman
-
Patent number: 12048735Abstract: The present invention provides, in part, formulations comprising an alkaline phosphatase (AP)-based agent. Particularly, modified-release powder formulations comprising an AP-based agent are provided which release a substantial amount of the AP-based agent in the intestines. Therapeutic uses of the formulations are also provided.Type: GrantFiled: March 29, 2021Date of Patent: July 30, 2024Assignee: Theriva Biologics, Inc.Inventors: Vincent Wacher, J. Blair West, Michael Kaleko, Christian Furlan Freguia
-
Patent number: 12048736Abstract: The present invention describes vaccine compositions for treatment and/or prevention against sea lice infestation in salmon. The present invention further describes nucleic acids, host cells, vectors and methods of using said vaccine for the prevention and/or treatment of sea lice infestation in salmon.Type: GrantFiled: October 1, 2021Date of Patent: July 30, 2024Assignee: Pharmaq ASInventors: Jose de Jesus de la Fuente Garcia, Marinela Contreras Rojo, Margarita Maria Villar Rayo, Marius Andre De Feijter Karlsen, Bjorn Erik Brudeseth, Karine Lindmo Yttredal, Christer Ross Wiik-Nielsen, Rolf Hetlelid Olsen, Liv Blom Hungerholdt
-
Patent number: 12048737Abstract: The invention pertains to the use of a tumor vaccine composed of two peptides of nine amino acids—the WT cryptic TERT572 (RLFFYRKSV, SEQ ID No: 1) expressed by tumor cells and its optimized variant TERT572Y (YLFFYRKSV, SEQ ID No: 2)—for treating cancer in a HLA-A*0201-positive patient having a non-immunogenic tumor expressing TERT.Type: GrantFiled: May 4, 2018Date of Patent: July 30, 2024Assignee: KRIPTIC PHARMACEUTICALS LIMITEDInventors: Kostantinos (Kostas) Kosmatopoulos, Jeanne Menez-Jamet, Catherine Gallou, Aude Rougeot
-
Patent number: 12048738Abstract: The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably an mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific Membrane Antigen), PSCA (Prostate Stem Cell Antigen), and STEAP (Six Transmembrane Epithelial Antigen of the Prostate), The invention furthermore relates to a vaccine comprising an active (immunostimulatory) composition, and to the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (PCa), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related thereto.Type: GrantFiled: August 22, 2019Date of Patent: July 30, 2024Assignee: CureVac SEInventors: Jochen Probst, Ingmar Hoerr, Thomas Lander
-
Patent number: 12048739Abstract: The invention relates to capsular polysaccharides of Streptococcus pneumoniae. More specifically, the present invention relates to sized and purified capsular polysaccharides of Streptococcus pneumoniae serotypes 2, 15A, 15C & 35B and process for their preparation.Type: GrantFiled: September 23, 2019Date of Patent: July 30, 2024Assignee: Biological E LimitedInventors: Rajendar Burki, Vivek Babu Kandimalla, Rajan Sriraman, Ramesh Venkat Matur, Narender Dev Mantena, Mahima Datla, Veerapandu Sangareddy
-
Patent number: 12048740Abstract: Provided are topical delivery systems and methods for treating and/or preventing a disease or disorder in a subject, or for eliciting an immune response in a subject including applying, to at least a portion of the subject's post-auricular region, a topical delivery system including a therapeutically effective amount of a topical pharmaceutical composition comprising at least one active agent and a pharmaceutically acceptable carrier and/or adjuvant. The topical pharmaceutical composition can include a topical immunogenic composition. The topical delivery system can further include a flexible substrate in communication with the topical immunogenic composition. The subject can be a pediatric subject.Type: GrantFiled: July 7, 2020Date of Patent: July 30, 2024Assignee: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITALInventor: Lauren O. Bakaletz
-
Patent number: 12048741Abstract: Recombinant viruses include one or more SHREK proteins and are thereby rendered non-infective and can be safely used in vaccines, e.g. to treat or prevent infections and to eliminate e.g. latent virus reservoirs.Type: GrantFiled: September 24, 2020Date of Patent: July 30, 2024Assignee: GEORGE MASON UNIVERSITYInventors: Yuntao Wu, Deemah Dabbagh, Sijia He, Brian Hetrick
-
Patent number: 12048742Abstract: The present disclosure provides an immunogenic composition comprising: a) i) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; ii) an HCV E1 polypeptide; or iii) an HCV E2 polypeptide; b) a polypeptide (also referred to herein as a “T-cell epitope polypeptide” or an “HCV T-cell epitope polypeptide”) comprising T-cell epitopes (e.g., CD4+ and CD8+ T-cell epitopes that are conserved among some HCV genotypes and that are presented through one or multiple HLA alleles common within the human population) present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide.Type: GrantFiled: March 14, 2019Date of Patent: July 30, 2024Assignee: The Governors of the University of AlbertaInventors: Michael Houghton, Abdolamir Landi, Michael Logan, John L. Law, Chao Chen, Darren Hockman
-
Patent number: 12048743Abstract: This invention relates to the use of S. pneumoniae protein antigens, such as NanA, PiuA and Sp0148, as carriers for immunogenic S. pneumoniae capsular polysaccharide. This may be useful for example in glycoconjugate vaccines able to generate a protective immune response against multiple capsular serotypes. Glycoconjugates, vaccine compositions and methods of manufacture and use are provided.Type: GrantFiled: May 2, 2019Date of Patent: July 30, 2024Assignee: London School of Hygiene & Tropical Medicine and UCL Business LTDInventors: Brendan Wren, Jeremy Brown, Jon Cuccui
-
Patent number: 12048744Abstract: The invention provides for a RANKL-specific antagonistic agent recognizing human platelet-expressed receptor activator of nuclear factor kappa-B ligand (pRANKL), for use in treating a cancer patient to prevent or reduce premetastatic lesions in blood.Type: GrantFiled: September 17, 2020Date of Patent: July 30, 2024Assignee: Probiocon GmbHInventors: Helmut Salih, Ludger Grosse-Hovest, Andreas Herrmann, Hans-Georg Kopp, Stefanie Maurer
-
Patent number: 12048745Abstract: Compositions and methods of their use to detect and treat anti-PD1 therapy resistance are provided herein. Compositions that immunospecifically bind and deplete dysfunctional T cells are provided. The dysfunctional T cells that are depleted include CD38+PD-1+ T cells, CD38+CD8+ T-cells, or both. The dysfunctional T cells can be depleted, for example, by administering an antibody or fusion protein that specifically binds to dysfunctional T cells and promotes their depletion. In one embodiment the antibody is a bispecific antibody that can be specific for CD38 and CD8, or it can be specific for CD38 and PD-1. Also disclosed is a method of detecting and treating anti-PD1 therapy resistance by measuring the amount of CD38+PD1+CD8 T cells in blood or tissue samples obtained from a subject prior to anti-PD1 therapy and administering an anti-CD38/CD8 or anti-CD38/PD-1 depleting/blocking antibody to the subject prior to anti-PD1 therapy.Type: GrantFiled: May 1, 2019Date of Patent: July 30, 2024Assignee: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.Inventors: Samir N. Khleif, Vivek Verma, Seema Gupta
-
Patent number: 12048746Abstract: Featured herein are pharmaceutical compositions and formulations containing an interleukin-6 (IL-6) antagonist, e.g., an IL-6 antibody molecule, designed for administration for a subject. The pharmaceutical compositions and formulations provided herein are suitable for use in manufacture of medicaments or methods of treating subjects with IL-6 associated diseases, e.g., ocular diseases associated with elevated levels of IL-6.Type: GrantFiled: August 31, 2021Date of Patent: July 30, 2024Assignee: HOFFMANN-LA ROCHE INC.Inventors: Grigorios Zarbis-Papastoitsis, Patricia Lowden
-
Patent number: 12048747Abstract: This invention provides amine-linked C3-glutarimide Degronimers for therapeutic applications as described further herein, and methods of use and compositions thereof as well as methods for their preparation, wherein the C3-glutarimide Degronimers have the formula:Type: GrantFiled: December 14, 2020Date of Patent: July 30, 2024Assignee: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Chi-Li Chen, Martin Duplessis, Minsheng He, Kiel Lazarski
-
Patent number: 12048748Abstract: This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.Type: GrantFiled: November 11, 2021Date of Patent: July 30, 2024Assignee: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Kiel Lazarski, Ryan E. Michael
-
Patent number: 12048749Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.Type: GrantFiled: April 29, 2022Date of Patent: July 30, 2024Assignee: REVOLUTION MEDICINES, INC.Inventors: G. Leslie Burnett, James Bradley Aggen, Jennifer Pitzen
-
Patent number: 12048750Abstract: Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the cartilage or kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.Type: GrantFiled: August 15, 2022Date of Patent: July 30, 2024Assignee: Blaze Bioscience, Inc.Inventors: Stacey J. Hansen, Claudia Jochheim, Dennis M. Miller, Natalie Winblade Nairn, Julia E. Novak, Mark R. Stroud, Valorie R. Wiss, Kelly Byrnes-Blake, Scott Presnell
-
Patent number: 12048751Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.Type: GrantFiled: February 22, 2022Date of Patent: July 30, 2024Assignee: MEDIBEACON INC.Inventors: Richard B. Dorshow, Steven J. Hanley, Phillip I. Tarr
-
Patent number: 12048752Abstract: Disclosed is a suspension of gas-filled microbubbles in a physiologically acceptable liquid carrier comprising a lipid mixture of a first lipid having transition temperature of about 41° C. such as DPPC or DPPG, a second lipid having transition temperature of about 55° C. such as DSPC or DSPG, and a PEGylated DSPE such as DSPE-PEG2000, DSPE-PEG3000, or DSPE-PEG5000, and methods of preparation thereof.Type: GrantFiled: June 1, 2022Date of Patent: July 30, 2024Assignee: Trust BioSonics Inc.Inventors: ChungHsin Wang, ChienYu Ting
-
Patent number: 12048753Abstract: Provided herein are methods for producing site specific PEG modifications to single domain antibodies (e.g., VHHs). Methods for producing site-specifically conjugated bivalent single domain antibodies (e.g., VHHs) are also provided. Methods for labeling (e.g., with a fluorophore or radionuclide) site-specifically PEGylated single domain antibodies and site-specifically conjugated bivalent single domain antibodies are also provided.Type: GrantFiled: October 1, 2016Date of Patent: July 30, 2024Assignee: Whitehead Institute for Biomedical ResearchInventors: Mohammad Rashidian, Hidde L. Ploegh
-
Patent number: 12048754Abstract: A dental desensitizer, including, by weight: 1-20 parts of a protein modified by polyethylene glycol; 1-10 parts of tris(2-carboxyethyl) phosphine hydrochloride; 1-3 parts of calcium chloride; and 2-20 parts of a pH regulator.Type: GrantFiled: June 30, 2021Date of Patent: July 30, 2024Assignee: MEIYOU (XI'AN) BIOTECHNOLOGY CO., LTD.Inventors: Peng Yang, Chen Li
-
Patent number: 12048755Abstract: Disclosed are microcapsule compositions having microcapsules suspended in an aqueous phase. Each of the microcapsules has a single core-shell structure and contains a microcapsule core and a microcapsule wall encapsulating the microcapsule core. The microcapsule compositions include a pectin. Also disclosed are preparation methods and use of the microcapsule compositions in consumer products.Type: GrantFiled: December 17, 2019Date of Patent: July 30, 2024Assignee: INTERNATIONAL FLAVORS & FRAGRANCES INC.Inventors: Li Xu, Yabin Lei, Ronald Gabbard, Lewis Michael Popplewell
-
Patent number: 12048756Abstract: A pigment suspension is provided. In one example, the pigment suspension includes a) at least one colorant compound selected from the group of pigments, b) at least one C1-C10 alcohol, c) at least one diol, d) at least one thickening agent, and e) water. A method for dyeing keratinous material and a multi-component packaging unit (kit-of-parts) for dyeing keratinous material including a pigment suspension are also provided.Type: GrantFiled: October 16, 2020Date of Patent: July 30, 2024Assignee: HENKEL AG & CO. KGAAInventors: Rene Krohn, Thomas Hippe, Jessica Brender, Stefan Hoepfner
-
Patent number: 12048757Abstract: An embossed effect pigment includes a metallic substrate in platelet form with embossed structure having a periodic pattern with diffractive elements, said substrate having been produced by PVD methods, wherein the substrate has an elemental metal content of 80% to 100% by weight, based on the substrate, and wherein the effect pigment has been treated with a leafing additive for surface modification. A method of manufacture of an embossed effect pigment includes suspending a metallic substrate in in at least one solvent, adding a leafing additive to the suspension including the metallic substrate in the at least one solvent and stirring the suspension including the leafing additive, and separating the embossed effect pigment from the at least one solvent.Type: GrantFiled: February 15, 2023Date of Patent: July 30, 2024Assignee: Eckart GmbHInventors: Christine Schilling, Ann-Katrin Gebhard, Ulrich Schmidt, Oliver Struck
-
Patent number: 12048758Abstract: The present invention relates to a preserving agent for a cosmetic composition, comprising 4-(3-ethoxy-4-hydroxyphenyl)-2-butanone and a second compound chosen from salicylic acid, the compounds of formula (II), salts thereof, esters thereof with an alcohol containing from 1 to 4 carbon atoms, and a mixture of these compounds. The present invention also relates to the use of the preserving agent for preserving cosmetic compositions. The present invention also relates to a cosmetic composition comprising the above preserving agent. Finally, the present invention relates to the use of the cosmetic composition for treating keratin fibres, preferably human keratin fibres such as the hair.Type: GrantFiled: December 20, 2017Date of Patent: July 30, 2024Assignee: L'OREALInventors: Gaelle Farhi, Gaelle Moneuze, Damien Drillon, Julien Galvan
-
Patent number: 12048759Abstract: The disclosure relates to compositions for treating keratinous substrates, such as the hair, comprising at least one monoamine and at least one carboxylic acid, as well as systems and methods for treating keratinous substrates with the compositions.Type: GrantFiled: November 19, 2021Date of Patent: July 30, 2024Assignee: L'OREALInventors: Kimberly Christine Dreher, Gérard Provot, Dariusz Danielski, Fabien Pascal Boulineau, Caroline Rahmouna Françoise Goget, Anthony Potin, Allison Chin, Michael Degeorge, Mara Applebaum, Mary Abraam Soliman, Ashley Ann Figatner, Megan Pauker, Emmanuel Appiah-Amponsah
-
Patent number: 12048760Abstract: Provided are hair treatment compositions comprising a polyurethane-urea crosslinked by at least one multi-functional chain extender, and uses thereof.Type: GrantFiled: April 26, 2019Date of Patent: July 30, 2024Assignee: Living Proof, Inc.Inventors: Soo-Young Kang, Zhaoxia Ji, Ling-Fang Tseng, Dinara A. Villanueva
-
Patent number: 12048761Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion. In particular, the present invention relates to a method of treating retinal capillary non-perfusion in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a ROCK inhibitor.Type: GrantFiled: October 12, 2016Date of Patent: July 30, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE), UNIVERSITÉ PARIS DESCARTES, UNIVERSITÉ PARIS DIDEROT—PARIS 7, FONDATION ASILE DES AVEUGLES, SORBONNE UNIVERSITÉInventors: Francine Behar-Cohen, Patricia Crisanti-Lassiaz
-
Patent number: 12048762Abstract: A method includes combining nicotine with a liquid carrier to form a liquid mixture and spray drying the liquid mixture to form a first plurality of particles. The first pluralities of particles are then milled to form a second plurality of particles.Type: GrantFiled: September 7, 2022Date of Patent: July 30, 2024Assignee: Philip Morris Products S.A.Inventor: Nicolo Volpe
-
Patent number: 12048763Abstract: Disclosed herein are methods and compositions comprising atropine and a polymer in a gel formulation for decreasing saliva production and treating sialorrhea.Type: GrantFiled: October 31, 2022Date of Patent: July 30, 2024Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Venkata K. Yellepeddi, Nancy Alice Murphy, Hamidreza S. Ghandehari, Harlan R. Muntz, Bhuvanesh Kumar Yathavan, Kevin Watt
-
Patent number: 12048764Abstract: An aqueous pharmaceutical solution for use in the treatment of diseases of the central nervous system (CNS), comprises at least 5 mg/ml dissolved levodopa and has a pH in the range of 3.0 to 8.5. The solution is provided by mixing a) an aqueous stock solution comprising levodopa and having a pH of less than 2.8 at 25° C., and b) an aqueous buffering solution having a pH of at least 4.0 at 25° C. for increasing the pH of the stock solution. The aqueous pharmaceutical solution is administered to a subject suffering from a disease of the CNS shortly after mixing of the aqueous stock solution and the aqueous buffering solution. A kit for administration of the aqueous pharmaceutical solution includes a bag comprising two parts and a removable or perforable barrier between the two parts.Type: GrantFiled: February 28, 2023Date of Patent: July 30, 2024Assignee: DIZLIN PHARMACEUTICALS ABInventors: Elias Eriksson, Nil Dizdar Segrell, Mats Ehrnebo, Leif Bring
-
Patent number: 12048765Abstract: The present invention provides a liposome encapsulating an autoantigen, wherein the liposome has a size comprised from 500 to 15000 nm and the liposome membrane comprises phosphatydilserine (PS) in an amount comprised from 10 to 40% by weight with respect to the total membrane liposomal composition. Pharmaceutical or veterinary compositions comprising a therapeutically effective amount of said liposome are also provided. Further, the invention provides liposomes and pharmaceutical or veterinary compositions as defined above for use as a medicament, particularly for the treatment of autoimmune diseases. Finally the present invention provides liposomes and pharmaceutical or veterinary compositions as defined above for use in the restoration of tolerance to self in a patient suffering from an autoimmune disease.Type: GrantFiled: January 16, 2015Date of Patent: July 30, 2024Assignees: FUNDACIO INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SLUT GERMANS TRIAST PUJOL, FUNDACIÓ INSTITUT CATALÀ DE NANOCIÈNCIA I NANOTECNOLOGIA, INSTITUCIÒ CATALANA DE RECERCA I ESTUDIS AVANCATSInventors: Daniel Maspoch Comamala, Antonia Maria Cano Sarabia, Marta Vives Pi, Irma Pujol Autonell, Juan Verdaguer Autonell
-
Patent number: 12048766Abstract: The disclosure relates generally to gamma polyglutamated tetrahydrofolate compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated tetrahydrofolate, and methods of making and using the gamma polyglutamated tetrahydrofolate compositions to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and autoimmune diseases such as rheumatoid arthritis). The disclosed compositions also have uses in combination therapy with one or more therapeutic agents to enhance the effectiveness or to reduce the toxicities associated with the therapeutic agent(s).Type: GrantFiled: February 7, 2019Date of Patent: July 30, 2024Assignee: L.E.A.F. HOLDINGS GROUP LLCInventors: Clet Niyikiza, Victor Mandla Moyo
-
Patent number: 12048767Abstract: The disclosure relates generally to gamma polyglutamated pralatrexate compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated pralatrexate, and methods of making and using the gamma polyglutamated pralatrexate compositions to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and autoimmune diseases such as rheumatoid arthritis).Type: GrantFiled: February 7, 2019Date of Patent: July 30, 2024Assignee: L.E.A.F. HOLDINGS GROUP LLCInventors: Clet Niyikiza, Victor Mandla Moyo
-
Patent number: 12048768Abstract: This disclosure relates to gastro-resistant, controlled release dosage forms comprising Compound (I): or a pharmaceutically acceptable salt and/or solvate thereof, the pharmacokinetic properties of these dosage forms, and the preparation of the same. The novel dosage forms disclosed herein are useful in reducing the risk of QT prolongation in a subject and in treating a disorder in a subject in need thereof, e.g., a subject diagnosed with schizophrenia, for example, in treating the negative symptoms in a subject diagnosed with schizophrenia having the CYP2D6 EM genotype.Type: GrantFiled: June 15, 2022Date of Patent: July 30, 2024Assignee: Minerva Neurosciences, Inc.Inventors: Jay Saoud, Remy Luthringer, Sandra Werner, Nadine Noel, Emmanuelle Georgi
-
Patent number: 12048769Abstract: Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.Type: GrantFiled: July 24, 2020Date of Patent: July 30, 2024Assignee: Nalpropion Pharmaceuticals LLCInventors: Anthony A McKinney, Gary D. Tollefson, Eckard Weber, Richard Soltero
-
Patent number: 12048770Abstract: The present invention relates to a transdermal therapeutic system for the transdermal administration of guanfacine comprising a guanfacine-containing layer structure, said guanfacine-containing layer structure comprising: A) a backing layer; and B) a guanfacine-containing layer; wherein the transdermal therapeutic system comprises at least one silicone acrylic hybrid polymer.Type: GrantFiled: October 11, 2018Date of Patent: July 30, 2024Assignees: LTS LOHMANN THERAPIE-SYSTEME AG, DOW SILICONES CORPORATIONInventors: Marco Emgenbroich, Eva-Marie Prinz, Elke Klein, Heike Kluth, Xavier Thomas, Linda Sue Nartker
-
Patent number: 12048771Abstract: A multifunctional microstructure patch is provided. The multifunctional microstructure patch, according to one embodiment of the present invention, comprises: a base layer having an opening part formed in the center thereof; a plurality of microstructures formed on one surface of the base layer and comprising a first drug; and a cover layer detachably bonded on the other surface of the base layer along the periphery of the opening part, and formed so as to cover the opening part.Type: GrantFiled: October 4, 2019Date of Patent: July 30, 2024Assignees: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY, JUVIC INCInventors: Hyungil Jung, Huisuk Yang
-
Patent number: 12048772Abstract: An apparatus for decontaminating and storing lab instruments such as pipettes. A carousel feature of the apparatus provides convenient access and allows multiple items to be decontaminated at the same time. The ultraviolet lamp directs UV radiation to surface contaminations of the instruments and effectively eliminates various microorganisms.Type: GrantFiled: June 7, 2023Date of Patent: July 30, 2024Assignee: MTC Bio. IncInventors: Edward Varga, Walter Demsia
-
Patent number: 12048773Abstract: A self-sanitizing surface structure configured to selectively refract light, a method of fabricating a self-sanitizing surface configured to selectively refract light, and a method of decontaminating a surface using selectively refracted light. A waveguide including a support layer below a propagating layer is positioned over a substrate as a self-sanitizing layer. In the absence of a contaminant or residue on the waveguide, UV light injected into the propagating layer is constrained within the propagating layer due to total internal reflection. When a residue is present on the self-sanitizing surface structure, light may be selectively refracted at or near the interface with the residue along the side of the waveguide to destroy the residue. The self-sanitizing surface structure may be configured is to refract a suitable amount of UV light in response to a particular type of residue or application.Type: GrantFiled: September 11, 2023Date of Patent: July 30, 2024Assignee: HRL LABORATORIES, LLCInventors: Adam F. Gross, Kevin Geary, Shanying Cui
-
Patent number: 12048774Abstract: The present invention relates to a method for decomposing peracetic acid and a method for culturing microorganisms using the decomposition method. The cultivation of microorganisms using the method of the present invention allows an effective removal of the peracetic acid used in a culture medium for sterilization.Type: GrantFiled: December 24, 2019Date of Patent: July 30, 2024Assignee: N-CELL CO., LTD.Inventors: Jong-Hee Kwon, Chang-Ho Cho
-
Patent number: 12048775Abstract: The present disclosure provides methods of stabilizing surgical screws comprising the intraoperative mixing of reactive putties to yield a homogenous putty composition (HPC) into which the screw is inserted, wherein the HPC comprises a polyurethane or polyurethane urea copolymer, one or more particulate materials, and one or more additive materials.Type: GrantFiled: August 6, 2021Date of Patent: July 30, 2024Assignee: Abyrx, Inc.Inventors: Richard L. Kronenthal, Aniq Darr, John Pacifico
-
Patent number: 12048776Abstract: A porous material suitable for implant is disclosed comprising a large plurality of substantially spherical intercalated hollows in a polymer. The hollows are formed by combining the polymer with a fugitive material under heat and pressure and subsequently removing the fugitive material to reveal the hollows. Intercalation can be increased by subjecting the fugitive material to a coalescing compacting process prior to combining the fugitive material with the polymer. The porous material can be combined with a solid material such as a solid polymer to fabricate complex implantable materials with a variety of features.Type: GrantFiled: November 12, 2019Date of Patent: July 30, 2024Assignee: GROUPE PPD INC.Inventors: Daniel Morrissette, Vincent Morrissette
-
Patent number: 12048777Abstract: The present invention is directed to a nerve regeneration conduit including a resorbable tube having a matrix therein. The matrix is characterized by substantially parallel, axially aligned pores extending the length of the matrix. The matrix is formed by the axial freezing of a slurry having little or no significant radial thermal gradient during the freezing process. The matrix is used to bridge the gap between the severed ends of a nerve and provide a scaffold for nerve regeneration.Type: GrantFiled: May 5, 2020Date of Patent: July 30, 2024Assignee: Integra LifeSciences CorporationInventor: Simon J. Archibald
-
Patent number: 12048778Abstract: The present invention relates to a process for sterilizing implantable biomaterials. In particular, the invention relates to a process for sterilizing collagen-containing implantable biomaterials and storage thereafter.Type: GrantFiled: July 28, 2020Date of Patent: July 30, 2024Assignee: Anteris Aus Operations Pty Ltd.Inventor: William Morris Leonard Neethling
-
Patent number: 12048779Abstract: Medical devices having engineered mechanically functional cartilage from adult human mesenchymal stem cells and method for making same.Type: GrantFiled: October 21, 2021Date of Patent: July 30, 2024Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Sarindr Bhumiratana, Gordana Vunjak-Novakovic
-
Patent number: 12048780Abstract: The technology relates to a 3D printed hydrogel formed from a maleimide containing polymer cross-linked using a bis-thiol containing cross-linking agent having at least two thiol functional groups, processes for preparing the 3D printed hydrogel, and uses thereof.Type: GrantFiled: July 23, 2019Date of Patent: July 30, 2024Assignee: NewSouth Innovations Pty LimitedInventors: Robert Hadinoto Utama, Vincent Tit Guan Tan, John Justin Gooding
-
Patent number: 12048781Abstract: A three-dimensional biomimetic artificial blood vessel that is biodegradable and biocompatible, is inspired by the morphological structure and physiological role of blood vessels having small diameter in the human circulatory system. A method of production by electro spinning is also disclosed.Type: GrantFiled: May 16, 2018Date of Patent: July 30, 2024Inventors: Oguzhan Gunduz, Ahmet Zeki Sengil, Faik Nuzhet Oktar, Nazmi Ekren, Selami Cakmak, Ahmet Talat Inan, Mehmet Onur Aydogdu, Esra Altun
-
Patent number: 12048782Abstract: A fluid flow circuit assembly for a biological fluid processing device, comprising a PVC tubing comprising a polymeric plasticizer and/or a high molecular weight plasticizer having a molecular weight of 540 g/mol or more. The fluid flow circuit assembly also comprises a medical device component comprising a bond surface to which the PVC tubing is bonded by a solvent, wherein the bond surface comprises a polyester elastomer, plasticized PVC, and/or a polycarbonate.Type: GrantFiled: June 29, 2018Date of Patent: July 30, 2024Inventor: Craig Sandford